# A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

> **NCT07669051** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 36 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** ivonescimab plus EGFR-TKI.

## Key facts

- **NCT ID:** NCT07669051
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07669051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07669051, "A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07669051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*